1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Blue Acquisition Corp. (BACC) and Blockfusion entered a Sixth Amendment to their business combination agreement on September 21, 2026. The amendment raises the maximum earnout shares for certain Blockfusion stockholders to 15,000,000 and replaces the CoreWeave warrant with a Pubco warrant, which changes how Pubco shares are counted at closing.
Maximum earnout shares increased to 15,000,000, delivered in thirds at common stock VWAPs of $13.00, $15.00 and $17.00 per share.
CoreWeave warrant for 2,786,624 Blockfusion shares is cancelled and replaced by a Pubco warrant for 2,870,813 Class A shares at $7.4643 per share.
Other terms of the business combination agreement remain in effect; closing still depends on shareholder approval and other conditions.
Brunswick Corporation said Chairman and CEO David Foulkes will retire at the end of 2026. Executive Aine Denari becomes CEO and David Everitt becomes Non-Executive Chairman, both effective January 1, 2027, which sets a defined leadership handover for shareholders. The filing also discloses retention equity awards to three senior executives, including the CFO.
David Foulkes notified the Board on September 17, 2026 of his retirement as Chairman and CEO, effective December 31, 2026
Aine Denari, 54, currently EVP and President of Navico Group and CTO, becomes CEO with a base salary of $1,150,000
David Everitt, current Lead Independent Director, becomes Non-Executive Chairman effective January 1, 2027
Retention RSU grants with grant-date values of $3,000,000 to CFO Ryan Gwillim and $1,700,000 each to John Buelow and Brenna Preisser
Vista Gold entered into an Arrangement Agreement on September 20, 2026, under which Artemis Gold would acquire all of Vista's common shares through a court-approved plan of arrangement. Vista shareholders would receive 0.0966 Artemis Gold shares for each Vista share, which the companies say implies US$2.83 per share and a 29% premium to Vista's 20-day volume-weighted average price. The deal requires Vista shareholder approval and other regulatory and court approvals, and the companies expect completion in January 2027.
Exchange ratio of 0.0966 Artemis Gold common shares per Vista Gold share, implying US$2.83 per share and a total transaction value of about US$427 million on a 100% basis
Premium of 29% to the 20-day VWAP as of September 18, 2026, and 25% to the last closing price, according to the companies
Vista must pay a termination fee of US$18,148,536 in certain circumstances, and either party may terminate if the Effective Time has not occurred by April 15, 2027
Directors and officers have signed voting support agreements, and Vista expects its proxy statement to be mailed in November 2026 with a shareholder meeting in December 2026
On September 15, 2026, Algorhythm Holdings closed its purchase of substantially all assets of Azure Energy, LLC, paying entirely in company securities valued at $23,000,000. The same day, CEO Gary Atkinson and CFO Alex Andre were terminated, Andrew Thompson became CEO, and the company issued a $4,025,000 secured note in an exchange for its Series A Preferred Stock. The common shares issued equal 19.99% of outstanding common stock, and the filing states the company is now seeking to shift its operating focus to renewable power.
Closed September 15, 2026; price of $23,000,000 paid in 4,076,312 common shares (19.99% of outstanding as of September 14, 2026) and 22,038 Series B Preferred shares
Option to buy 79.0286% of Azure S.R.L. equity for $30,000,000 within 36 months; up to 50% of exercise price payable in cash
Andrew Thompson appointed CEO effective September 15, 2026; Gary Atkinson and Alex Andre employment terminated not for cause; Atkinson also resigned from the board
Streeterville exchanged 3,500 Series A Preferred shares for a $4,025,000 Secured Pre-Paid Purchase #5 bearing 9% interest, maturing three years from September 15, 2026
Woodward plans to cease operations at its Santa Clarita, California, facility no later than December 2027 and move military flight control actuation production to its Spartanburg, South Carolina campus. The company also agreed to sell certain legacy product lines and the Santa Clarita campus, with that sale expected to close in fiscal 2027. Woodward expects cumulative pre-tax charges of $34 million to $47.5 million, mostly cash costs, which shareholders will bear as the actions are completed.
Estimated cumulative pre-tax charges of $34 million to $47.5 million, including $23 million to $29 million of employee-related costs
About 400 roles at the Santa Clarita facility are expected to be affected
Santa Clarita operations to cease no later than December 2027; Spartanburg facility expected to go online in summer 2027
Divestiture of certain product lines and the Santa Clarita campus expected to close in fiscal year 2027
Magnite appointed Brian Gephart as Chief Financial Officer effective October 1, 2026, succeeding David Day, who announced his retirement. Gephart has been the company's Chief Accounting Officer since June 2021, and the company also named Haas Sullivan as Chief Accounting Officer effective the same date. The filing describes leadership succession and compensation terms, not financial results.
Brian Gephart, age 47, becomes CFO effective October 1, 2026, succeeding retiring CFO David Day
Gephart's equity award totals $2.25 million: $1,575,000 in RSUs granted October 1, 2026 and $675,000 in PSUs expected in 2027
Haas Sullivan, age 43, becomes Chief Accounting Officer effective October 1, 2026, with an RSU grant of approximately $600,000
IB Acquisition Corp. entered into an equity purchase facility of up to $50 million and a securities purchase agreement for senior secured convertible notes, both tied to its pending business combination with GNQ Insilico. The initial PIPE closing of $16,470,588 is set to occur just before the business combination closes, with potential additional closings up to $90 million. The notes carry a 12% interest rate and a 12-month maturity, and their conversion could dilute existing shareholders.
Equity purchase facility allows the company to sell up to $50.0 million of Class A common stock to an institutional investor over up to 36 months.
Initial PIPE closing of $16,470,588 in senior secured convertible notes, with potential additional closings up to $90,000,000.
PIPE notes bear 12% annual interest, rise to an 18% default rate, mature in 12 months and convert at an initial $10.00 per share.
Company issued a $675,000 convertible commitment note to the equity facility investor.
EverCommerce said President Matthew Feierstein resigned on September 18, 2026, as president of the company and CEO of its EverPro unit, to pursue other opportunities. The filing says the resignation does not stem from any disagreement over company operations, policies or practices. The departure takes effect October 9, 2026, unless the company and Mr. Feierstein agree on a later date, and he will serve as a paid consultant afterward.
Resignation dated September 18, 2026; effective October 9, 2026, or a later mutually agreed date
Eligible for a 2026 annual target bonus, prorated for days employed in 2026, subject to continued employment and a release of claims
Vested stock option exercise period extended to 35 months after termination, or the original expiration date if earlier
Consultant on an as-needed basis through December 31, 2026, at $500 per hour
Weave Communications disclosed that early termination of the U.S. antitrust waiting period under the HSR Act was granted on September 21, 2026, for its pending acquisition by Francisco Partners-affiliated Willow Parent, LLC. This satisfies one closing condition, and the merger is expected to close in the fourth quarter of 2026, subject to stockholder approval and other customary conditions.
Early termination of HSR Act waiting period granted September 21, 2026
Merger agreement signed August 18, 2026 with Willow Parent, LLC and Willow Merger Sub, Inc., affiliates of Francisco Partners
Closing expected in the fourth quarter of 2026, subject to stockholder approval
Preliminary proxy statement was filed with the SEC on September 15, 2026; a special stockholder meeting will be announced
Optimum Communications said its previously issued financial statements for fiscal 2025 and the first half of 2026 should no longer be relied upon, because it failed to recognize non-cash deferred tax benefits tied to two earlier impairment charges on its cable franchise rights. The restatements are expected to reduce previously reported net losses, but the company also expects to report a material weakness in internal control over financial reporting related to income taxes.
The restatement covers the 10-K for fiscal 2025, the 10-Qs for the periods ended September 30, 2025, March 31, 2026 and June 30, 2026, and the financial statements of subsidiary CSC Holdings, LLC.
Reported net losses would decline by approximately $430 million for the three and nine months ended September 30, 2025 and the year ended December 31, 2025, and by approximately $720 million for the quarter ended March 31, 2026 and the six
Cash balances, revenues, capital expenditures, cash flows, EBITDA and loss before income taxes are not affected, according to the filing.
The Audit Committee concluded on September 16, 2026 that the affected statements should not be relied upon; the figures remain preliminary and may change.
On September 21, 2026, Orion180 Insurance Group Inc. completed its initial public offering of 20,000,000 Class A common shares at $12.00 per share, raising gross proceeds of $240.0 million before underwriting discounts and commissions. The company's amended and restated certificate of formation and bylaws took effect the same day, and five new directors were elected to the board effective September 17, 2026.
Offering: 20,000,000 shares of common stock at $12.00 per share, with gross proceeds of $240.0 million before underwriting discounts and commissions
Charter: authorized capital of 400,000,000 Class A shares, 100,000,000 Class B shares and 50,000,000 undesignated preferred shares, all with $0.001 par value
Board: Kevin Bollinger, Samir Deshpande, Robert V. Deutsch, Lawrence E. McAlee and Kernan "Kip" Oberting elected effective September 17, 2026
Agreements: Registration Rights Agreement and Exchange Agreement with Kenneth Gregg, plus indemnification agreements with directors and executive officers
The European Commission granted marketing authorization for Ubeslo and Evlarco, obicetrapib-based treatments for primary hypercholesterolaemia or mixed dyslipidaemia, marking the first regulatory approval of obicetrapib worldwide. The company's partner Menarini holds European commercialization rights, and the approvals trigger milestone payments in the mid-teens of millions of euros, with up to an additional €833 million available on future milestones.
Approvals cover all EU Member States, Iceland, Liechtenstein and Norway
Ubeslo is obicetrapib 10 mg monotherapy; Evlarco is 10 mg obicetrapib plus 10 mg ezetimibe
EC requires a post-authorization efficacy study and final results from the PREVAIL cardiovascular outcomes trial
Menarini milestone payments in the mid-teens of millions of euros triggered by the authorizations
Industrial Logistics Properties Trust appointed Anthony Paula as Chief Financial Officer and Treasurer, effective October 1, 2026, replacing Tiffany R. Sy, who resigned effective September 30, 2026. A CFO change is a notable leadership transition, and the filing does not describe any change to financial results or guidance.
Anthony Paula, age 39, appointed CFO and Treasurer by the Board on September 16, 2026, effective October 1, 2026
Tiffany R. Sy resigned as CFO and Treasurer, effective September 30, 2026
Paula is a vice president at The RMR Group LLC, the company's manager, and is a certified public accountant
Paula will resign his vice president role at Diversified Healthcare Trust in connection with the appointment
Ethan Allen's Board said it has begun a formal, independent CEO succession process and has committed to naming the next CEO no later than June 30, 2027, the date Chairman, President and CEO M. Farooq Kathwari's employment agreement is scheduled to end. Kathwari will remain a non-executive Board member until the 2027 annual meeting, when he will step down. The filing reports no financial results, and the Board said the process will consider internal and external candidates.
Board committed to announcing the next CEO no later than June 30, 2027
Kathwari continues to lead management and will remain a non-executive director until the 2027 annual meeting
A nationally recognized executive search firm has been engaged to evaluate internal and external candidates
CVRx appointed John Landry, currently CFO of Nyxoah SA, as its Chief Financial Officer, succeeding Jared Oasheim, whose resignation was previously disclosed on June 8, 2026. Landry joins on October 12, 2026, and takes the CFO role the day after the company files its Form 10-Q for the quarter ending September 30, 2026. The filing lists a $500,000 initial base salary and initial equity awards equal to 0.80% of total common shares outstanding, which matters to shareholders as a senior finance transition.
John Landry appointed CFO; joins company October 12, 2026 and assumes the role the day after the Q3 2026 Form 10-Q is filed
Initial base salary of $500,000 with a 50% target cash incentive, pro-rated for fiscal 2026
Initial equity awards of 0.80% of total common shares outstanding, split 75% stock options and 25% RSUs
Jared Oasheim, who gave notice June 8, 2026, will remain for a transition period
Travere Therapeutics said CEO Eric Dube will step down as President, CEO and board member effective December 1, 2026, and Bradley L. Campbell, former CEO of Amicus Therapeutics, will succeed him in both roles on the same date. Dube will stay on as Executive Advisor through February 15, 2027, and his employment ends February 16, 2027, unless the two sides agree to an earlier date. The change is a planned leadership transition under agreements both parties signed on September 21, 2026.
Eric Dube's CEO and board roles end December 1, 2026; Bradley L. Campbell takes both roles that day.
Dube's employment is scheduled to end February 16, 2027, and he will serve as a consultant for up to 18 months after the resignation date.
Campbell's employment agreement sets a $1,000,000 base salary, a target bonus of 85% of base salary, and approximate equity grants of $8,250,000 in stock options and $8,250,000 in restricted stock units.
Dube will not be eligible for the 2027 cash bonus program and will receive no further stock awards, though existing awards keep vesting.
Turning Point Brands CEO Graham Purdy resigned for personal reasons and will also leave the board effective September 30, 2026. The board named Executive Chairman David E. Glazek as CEO effective October 1, 2026. The company reaffirmed its 2026 Modern Oral sales guidance but lowered the top of its EBITDA guidance range, which matters to shareholders because it signals a leadership transition alongside a narrower profit outlook.
Graham Purdy steps down as President and CEO and as a director effective September 30, 2026; the company says the departure is not related to any disagreement.
David E. Glazek, Executive Chairman since 2023 and a director since 2012, becomes CEO effective October 1, 2026.
2026 Modern Oral gross sales guidance of $330 million to $350 million and net sales guidance of $260 million to $270 million were reaffirmed.
Full-year 2026 EBITDA guidance was tightened to $70 million to $80 million from $70 million to $90 million.
Resources Connection, Inc. (RGP) said its board appointed Trisha Jenks, currently SVP and Corporate Controller, as Chief Accounting Officer effective October 3, 2026. The filing also references the previously announced resignation of CFO Jennifer Ryu, effective October 2, 2026, with Jessica Block named interim CFO effective October 3, 2026, so the finance leadership change is significant for shareholders.
Trisha Jenks, 50, appointed Chief Accounting Officer and principal accounting officer, effective October 3, 2026
CFO Jennifer Ryu resigning effective October 2, 2026; Jessica Block named interim CFO effective October 3, 2026
Jenks' annual base salary increased to $350,000; fiscal 2027 target bonus of $150,000, guaranteed subject to continued employment
Electra Therapeutics, Inc. closed its initial public offering on September 21, 2026, selling 23,333,334 shares of common stock at $15.00 per share, for approximately $350.0 million in gross proceeds before underwriting discounts and offering expenses. The company also filed an amended and restated certificate of incorporation and adopted amended and restated bylaws effective on the closing date.
IPO: 23,333,334 shares of common stock sold at $15.00 per share
Gross proceeds of approximately $350.0 million before underwriting discounts and estimated offering expenses
Restated certificate of incorporation filed with Delaware and restated bylaws adopted, both effective September 21, 2026
Full terms are described in the final prospectus filed September 18, 2026 under Rule 424(b)
Bloomia Holdings reported fiscal 2026 results for the year ended June 30, 2026, with revenue of $48.1 million, down slightly from $48.4 million, and a net loss attributable to the company of $11.2 million, or $4.43 per diluted share, versus a $2.6 million loss, or $1.45 per share, a year earlier. The loss reflects a $13.2 million non-cash impairment charge and excess production waste that the company attributes to an industry-wide mite issue, which pushed adjusted EBITDA to a loss of $0.5 million. Total debt fell to $21.7 million, which shareholders may weigh against the weaker operating results.
Fiscal 2026 revenue was $48.1 million, compared with $48.4 million in fiscal 2025.
Net loss attributable to Bloomia Holdings was $11.2 million, or $4.43 per diluted share, compared with a $2.6 million loss, or $1.45 per share.
Adjusted EBITDA was a loss of $0.5 million, compared with $2.0 million in fiscal 2025; the company cites over $2.5 million of excess waste.
Total debt decreased to $21.7 million at June 30, 2026, from $34.1 million at June 30, 2025.
Sajal Srivastava notified TriplePoint Venture Growth BDC Corp. (TPVG) on September 15, 2026, that he will resign as a director and as President and Chief Investment Officer, effective at the close of business on December 31, 2026. Ian Schworer was appointed Chief Investment Officer effective the same date, and the board will shrink from eight members to seven. The change shifts the leadership of the fund's investment function, but the filing does not discuss any effect on financial results.
Srivastava's resignation takes effect at the close of business on December 31, 2026; he will serve in his current roles until then.
The board, on September 18, 2026, reduced its size from eight members to seven, effective December 31, 2026.
Ian Schworer, 45, was appointed Chief Investment Officer effective December 31, 2026, and has worked at TriplePoint Capital since 2014, most recently as Chief Credit Officer.
The Company will pay no cash compensation or direct benefits to Schworer, who is an employee of TriplePoint Capital.
Beacon Financial Corporation said its President and Chief Executive Officer, Paul A. Perrault, is retiring effective September 21, 2026, and Sean A. Gray, its Chief Operating Officer, is taking over as President and CEO and joining the boards of the Company and Beacon Bank & Trust. The filing describes a twelve-month consulting arrangement with Mr. Perrault, including a $120,000 monthly consulting fee, and the filing does not report any financial results for the period.
Paul A. Perrault retires as President and CEO and resigns from both boards effective September 21, 2026.
Sean A. Gray, age 50, becomes President and CEO and joins the boards; he previously served as Chief Operating Officer since 2025.
Mr. Perrault's consulting agreement runs for twelve months at $120,000 per month and includes payment of his 2026 annual bonus based on actual performance.
PEDEVCO Corp. said its President and CEO J. Douglas Schick stopped serving as CEO and director on September 21, 2026, and Chief Operating Officer Reagan Tuck (R.T.) Dukes became interim President and CEO effective that day. The company says the change is not due to any disagreement, and Schick will stay on as a non-executive Senior Advisor through December 31, 2026.
Schick ceased to be President, CEO and a board member; Dukes named interim President and CEO effective September 21, 2026
Schick's separation agreement provides 2.5 times the sum of base salary and target bonus, plus a $255,000 payment in lieu of a 2026 annual bonus
Dukes, age 42, previously served as CEO of Century Natural Resources, LLC from June 2021 to October 2025
National CineMedia, through subsidiary NCM Holdings, completed its acquisition of Captivate on September 18, 2026, for $275.0 million in cash, subject to adjustments. The deal was funded with a new $275.0 million term loan, a $25.0 million revolving facility with $10.0 million drawn, and cash on hand, and it repaid the company's existing U.S. Bank credit facility. The filing adds a larger debt load at a 7.00% SOFR margin, which shareholders should weigh against the expanded screen network.
Captivate acquisition closed September 18, 2026, for $275.0 million, including a $5.0 million escrow for post-closing adjustments
$275.0 million term loan fully funded; $25.0 million revolver with $10.0 million drawn at closing
Facilities mature September 18, 2031, with a 7.00% per annum margin for SOFR borrowings
Maximum Total Net Leverage Ratio of 5.00:1.00, stepping down to 4.50:1.00 by December 31, 2029
Cue Biopharma announced positive topline results from a Phase 2 trial of CUE-221 in chronic spontaneous urticaria (CSU), conducted in China by Genesis Life Sciences with 145 participants. The primary endpoint was met at all dose levels, and the company plans a Phase 2b/3 CSU trial and a Phase 2 food allergy trial, subject to FDA review of the Phase 2 data. The filing contains clinical data only, with no revenue, earnings, cash or financing figures.
Primary endpoint (complete resolution of hives, HSS7=0, at week 12): 54% at 4 mg/kg, 53% at 2 mg/kg and 43% at 1 mg/kg, vs. 11% for placebo and 41% for omalizumab 300 mg.
Key secondary endpoint (UAS7=0 at week 12) was statistically significant at 4 mg/kg: 46% vs. 11% for placebo.
At week 28, 12 weeks off drug, complete resolution of hives was 60% at 4 mg/kg vs. 24% for omalizumab, a 36% difference (post hoc analysis).
No treatment-related serious adverse events and no hypersensitivity reactions, including anaphylaxis, were reported; the company will present full data at an upcoming scientific meeting.
Priority Technology Holdings signed a merger agreement on September 18, 2026, with an investor group led by Chairman and CEO Thomas Priore. The group will acquire the shares it does not already own for $8.05 per share in cash, an enterprise value of approximately $1.6 billion. Shareholders receive cash but would stop holding shares in a publicly listed company once the deal closes, which is expected in the first half of 2027.
Merger agreement dated September 18, 2026; $8.05 per share in cash; enterprise value of approximately $1.6 billion
The price is a 38% premium to the September 18, 2026 close and a 65% premium to the November 7, 2025 unaffected price
Approval requires a majority of shares not affiliated with the investor group; the company must pay a $15,750,000 termination fee in certain cases
Expected to close in the first half of 2027; common stock will no longer be listed on the Nasdaq Global Select Market
World Acceptance Corporation appointed John L. Calmes Jr., its executive vice president, chief financial and strategy officer and treasurer, as president and chief executive officer effective September 21, 2026. The filing sets his employment terms, including a $600,000 base salary and a guaranteed $300,000 bonus for fiscal 2027, and designates Scott McIntyre as principal financial officer for SEC reporting. The company said business through two and a half months of the second fiscal quarter is producing results similar to the first quarter.
Calmes succeeds the prior leadership effective September 21, 2026; he joined the company in December 2013 and has served as CFO and Treasurer since then, with the title of executive vice president since October 2018.
Employment agreement: $600,000 base salary, annual bonus opportunity up to 100% of base salary, guaranteed $300,000 bonus for fiscal 2027, and an additional long-term equity grant valued at $500,000.
Scott McIntyre, senior vice president of accounting, is designated principal financial officer for SEC reporting effective September 21, 2026, with no change to his compensation.
J. Tobin Turner, executive vice president and chief operating officer, is replaced as principal executive officer for SEC reporting purposes.
Avantor appointed Todd Garner as Executive Vice President and Chief Financial Officer, effective September 21, 2026, after he served as CFO of CONMED Corporation from January 2018 until March 2026. Steven Eck, who had been Interim CFO since June 24, 2026, will stop serving as interim CFO and remain Senior Vice President and Chief Accounting Officer, so the filing reports a change in the company's principal financial officer rather than a change in reported results.
Todd Garner's annual base salary is $700,000, with a target annual bonus of 80% of base salary and a one-time signing bonus of $150,000.
Garner's initial long-term equity grant has a target value of $1,500,000, split evenly between restricted stock units and stock options.
Garner will be eligible for a long-term incentive target annual grant of $3,000,000 in future years.
Steven Eck will continue as Senior Vice President and Chief Accounting Officer.
QuickLogic said CFO Elias Nader resigned effective September 18, 2026, to pursue other opportunities, and appointed James Sullivan, former CFO of Peraso Inc., as Senior Vice President of Finance and Chief Financial Officer effective October 5, 2026. The company said Nader's departure was not related to any disagreement on accounting, operating policies or practices, and that its previously announced third quarter 2026 guidance remains unchanged. The filing reports no new financial results, so the change replaces the finance chief without altering the company's stated outlook.
Elias Nader resigned as CFO effective close of business September 18, 2026, to pursue other opportunities.
James Sullivan, 58, becomes CFO effective October 5, 2026, and will also serve as principal financial and accounting officer.
Sullivan's offer letter sets a base salary of $340,000, a 50% target incentive bonus, a $10,000 signing bonus and $600,000 in restricted stock units, subject to Compensation Committee approval.
QuickLogic reaffirmed its third quarter 2026 guidance, which the company said remains unchanged.
Avantor appointed Todd Garner as executive vice president and chief financial officer, effective September 21, 2026. Garner previously served as CFO of CONMED Corporation from January 2018 until March 2026, and Steven Eck will stop serving as interim CFO while remaining chief accounting officer.
Todd Garner, age 57, becomes principal financial officer effective September 21, 2026; he was CFO of CONMED Corporation from January 2018 to March 2026
Garner's employment letter, dated September 17, 2026, sets an annual base salary of $700,000 and a target annual bonus of 80% of base salary
Garner receives a one-time signing bonus of $150,000 and an initial long-term equity grant with a target amount of $1,500,000
Steven Eck ceases to be interim CFO but continues as senior vice president and chief accounting officer
Axon issued and sold $1,150.0 million of 0% convertible senior notes due September 15, 2031, on September 18, 2026, including $150.0 million from the full exercise of the underwriters' over-allotment option. The initial conversion price is about $652.06 per share, compared with a last reported sale price of $442.08 on September 15, 2026, so conversion could dilute existing shareholders. The company said capped call transactions are expected to reduce that potential dilution, subject to a cap price of $1,049.94.
Principal of $1,150.0 million issued September 18, 2026, including $150.0 million from full exercise of the over-allotment option
Notes bear no regular interest and mature September 15, 2031; initial conversion rate of 1.5336 shares per $1,000 principal
Expected net proceeds of about $1,134.3 million if the over-allotment option is exercised in full, with about $114.9 million used for capped call transactions
Holders may require repurchase at par on or around March 20, 2031, and the company may redeem for cash on or after September 20, 2029, under specified conditions
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.